GDS Wealth Management Grows Holdings in DexCom, Inc. $DXCM

GDS Wealth Management boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 5.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 200,452 shares of the medical device company’s stock after purchasing an additional 11,134 shares during the period. GDS Wealth Management owned about 0.05% of DexCom worth $13,488,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Andra AP fonden bought a new position in shares of DexCom in the second quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom in the second quarter worth $26,000. SJS Investment Consulting Inc. grew its stake in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. bought a new position in DexCom in the 3rd quarter valued at $29,000. Finally, Sound Income Strategies LLC increased its position in shares of DexCom by 83.8% during the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 285 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total transaction of $171,599.30. Following the transaction, the director owned 35,088 shares of the company’s stock, valued at $2,071,946.40. This trade represents a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is currently owned by corporate insiders.

DexCom Price Performance

DexCom stock opened at $72.86 on Friday. The firm has a market capitalization of $28.42 billion, a P/E ratio of 40.48, a PEG ratio of 1.31 and a beta of 1.48. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The business has a fifty day moving average price of $66.41 and a 200-day moving average price of $71.16.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the firm posted $0.45 EPS. The firm’s quarterly revenue was up 21.6% on a year-over-year basis. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on DXCM shares. Evercore ISI initiated coverage on shares of DexCom in a research report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target for the company. The Goldman Sachs Group dropped their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. JPMorgan Chase & Co. decreased their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, October 31st. UBS Group dropped their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. Finally, Barclays downgraded DexCom from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $80.00 to $71.00 in a research report on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $86.30.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.